Suppr超能文献

[医疗技术成本效益比及公共资金投入的阈值]

[Threshold values for cost-effectiveness ratio and public funding of medical technologies].

作者信息

Rabinovich Mordechai, Greenberg Dan, Shemer Joshua

机构信息

Maccabi Healthcare Services, Tel Aviv, Israel.

出版信息

Harefuah. 2007 Jun;146(6):453-8, 500.

Abstract

Rising healthcare costs, together with the rapid emergence of new and expensive medical technologies, have facilitated the use of economic analyses for making coverage decisions. The use of cost-effectiveness studies requires an external criterion (threshold value) for the cost-effectiveness ratio, below which funding would be recommended. Although such a threshold reflects the societal value of a full-quality life-year, currently accepted thresholds have been determined arbitrarily. Studies that screened hundreds of cost-effectiveness analyses have found that the most commonly used threshold is $US 50,000 for an additional QALY (Quality Adjusted Life-Year). This figure reflects the estimated cost per QALY to the US Medicare plan for funding a dialysis treatment for patients with chronic renal failure. While healthcare systems throughout the world, as in Israel, have not explicitly declared using a specific threshold for coverage decisions, some countries use an implicit threshold, above which the decision would usually be negative. In the UK and Australia, for instance, the implicit threshold is $US 50,000 to $US 60,000 per QALY. There are several suggestions to set a differential threshold value between countries, associated with their relative wealth, or between diverse disease and treatment characteristics, e.g. higher thresholds for life-saving treatments. Advantages of setting an explicit threshold include improved transparency and consistency of decisions, improved social equity and enhanced public credibility. Draw-backs might be the creation of an excessively mechanical decision-making process, without consideration of other relevant variables, such as severity of disease, existence of alternatives, or the economic burden to the patient. Adoption of a "flexible threshold" approach, in which the threshold is not the exclusive criterion for decision-making, might resolve these weaknesses. Utilization of the threshold concept is likely to expand in the coming years.

摘要

不断上涨的医疗成本,加上新的昂贵医疗技术的迅速涌现,推动了在医保覆盖决策中采用经济分析方法。成本效益研究的应用需要一个成本效益比的外部标准(阈值),低于该阈值时建议提供资金支持。尽管这样一个阈值反映了一个完全质量调整生命年的社会价值,但目前公认的阈值是任意确定的。对数百项成本效益分析进行筛选的研究发现,最常用的阈值是每增加一个质量调整生命年(QALY)50,000美元。这个数字反映了美国医疗保险计划为慢性肾衰竭患者提供透析治疗的每QALY估计成本。虽然世界各地的医疗系统,如以色列的医疗系统,没有明确宣布在医保覆盖决策中使用特定阈值,但一些国家使用隐含阈值,超过该阈值决策通常是否定的。例如,在英国和澳大利亚,隐含阈值是每QALY 50,000美元至60,000美元。有几种建议是根据国家的相对财富或不同的疾病和治疗特征设定不同的阈值,例如对挽救生命的治疗设定更高的阈值。设定明确阈值的优点包括提高决策的透明度和一致性、改善社会公平性以及增强公众可信度。缺点可能是创建一个过于机械的决策过程,而不考虑其他相关变量,如疾病严重程度、替代方案的存在或患者的经济负担。采用“灵活阈值”方法,即阈值不是决策的唯一标准,可能会解决这些弱点。在未来几年,阈值概念的应用可能会扩大。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验